
Long-acting HIV therapies promise greater convenience, but fewer doses alone may not solve adherence or access challenges. Lloyd Bibby and Pooja Goyal, MS(Pharm), discuss patient choice, weekly oral and injectable therapies, health system capacity, equitable access, and the real-world measures that will define success.







